Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL11511384 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL10991977 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL8935437 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL6543826 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL329089 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL9665914 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL10771774 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL9495 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL9507364 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL7455458 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| CN-104211624-A | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2014-12-17 | — | — | CN | disclosed |
| CN-101668738-B | Pleuromutilin derivatives for the treatment of microbial mediated diseases | NABRIVA THERAPEUTICS AG (AT) | 2014-10-15 | — | — | CN | disclosed |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2014-09-11 | — | — | US | disclosed |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2013-02-14 | — | — | US | disclosed |
| US-8153689-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2012-04-10 | — | — | US | disclosed |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2012-02-02 | — | — | US | disclosed |
| US-8071643-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2011-12-06 | — | — | US | disclosed |
| CN-101668738-A | Pleuromutilin derivatives for the treatment of microbial mediated diseases | NABRIVA THERAPEUTICS AG | 2010-03-10 | — | — | CN | disclosed |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2010-02-11 | — | — | US | disclosed |
| US-4318847-A | ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 1061/4885LMNA 4292/4885HSD17B10 2387/4885 |
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 852/4885LMNA 4184/4885HSD17B10 2454/4885 |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 1061/4885LMNA 4292/4885HSD17B10 2387/4885 |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | ALDH1A1 1122/4885LMNA 4468/4885HSD17B10 2577/4885 |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, ALPI | ALDH1A1 1565/4885LMNA 4358/4885HSD17B10 2154/4885 |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | ALDH1A1 1122/4885LMNA 4468/4885HSD17B10 2577/4885 |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 852/4885LMNA 4184/4885HSD17B10 2454/4885 |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, PLEC | ALDH1A1 654/4885LMNA 4210/4885HSD17B10 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.